Letters
Return of the postcode lottery
Opportunity cost of the Cancer Drugs Fund
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d622 (Published 01 February 2011) Cite this as: BMJ 2011;342:d622
- Jonathan Howell, consultant in public health1
- 1West Midlands Specialised Commissioning Team, Birmingham B16 9LD, UK
- jon.howell{at}wmsc.nhs.uk
Anyone involved with the Interim Cancer Drugs Fund (ICDF) will recognise the inconsistencies and contradictions in trying to make it work for drugs with poor clinical effectiveness.1 As an adviser to the regional ICDF clinical panel, I watch oncologists struggle with the poor quality clinical evidence on the proposed drugs. Many …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.